HUP9802651A2 - Oltóanyagok részecskék célba juttatásával végzett genetikai immunizálással kiváltott, sejtközvetített immunválasz stimulálására - Google Patents

Oltóanyagok részecskék célba juttatásával végzett genetikai immunizálással kiváltott, sejtközvetített immunválasz stimulálására

Info

Publication number
HUP9802651A2
HUP9802651A2 HU9802651A HUP9802651A HUP9802651A2 HU P9802651 A2 HUP9802651 A2 HU P9802651A2 HU 9802651 A HU9802651 A HU 9802651A HU P9802651 A HUP9802651 A HU P9802651A HU P9802651 A2 HUP9802651 A2 HU P9802651A2
Authority
HU
Hungary
Prior art keywords
antigen
genetic immunization
stimulation
cell
immune responses
Prior art date
Application number
HU9802651A
Other languages
English (en)
Inventor
Louis D. Falo
Kenneth L. Rock
Original Assignee
Dana-Farber Cancer Institute
University Of Pittsburgh Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, University Of Pittsburgh Of The Commonwealth System Of Higher Education filed Critical Dana-Farber Cancer Institute
Publication of HUP9802651A2 publication Critical patent/HUP9802651A2/hu
Publication of HUP9802651A3 publication Critical patent/HUP9802651A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány szerinti megőldás emlősben (az embert is beleértve)antigén-specifikűs imműnválasz stiműlálására alkalmas genetikaiimműnizálásra vőnatkőzik. A leírásban szemcsés főrmájú pőlinűkleőtidőkgazdasejtek, példáűl antigénbeműtató sejtek citőplazmájába történőcélba jűttatását ismerteti. Ezek a szemcsés főrmájú plinűkleőtidőkantigén tűlajdőnságú fehérjét vagy antigén tűlajdőnságúfehérjefragmenst kódőlnak, amely bejűt a célsejt citőplazmájába. Azantigén génjének espressziója antigén-specifikűs imműnválaszt, példáűlantigén-specifi-kűs citőtőxikűs T-limfőciták (CTL-ek) indűkálásáteredményezi, amelyek elpűsztítják a kárősődőtt sejteket, példáűldaganatős vagy vírűsfertőzött sejteket. ŕ
HU9802651A 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization HUP9802651A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53555695A 1995-09-28 1995-09-28

Publications (2)

Publication Number Publication Date
HUP9802651A2 true HUP9802651A2 (hu) 1999-02-01
HUP9802651A3 HUP9802651A3 (en) 2001-08-28

Family

ID=24134735

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802651A HUP9802651A3 (en) 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Country Status (15)

Country Link
EP (1) EP0863704A4 (hu)
JP (1) JPH11512724A (hu)
KR (1) KR19990063672A (hu)
CN (1) CN1201369A (hu)
AU (1) AU716497B2 (hu)
BG (1) BG102355A (hu)
CA (1) CA2233278A1 (hu)
CZ (1) CZ92998A3 (hu)
HU (1) HUP9802651A3 (hu)
NO (1) NO981386L (hu)
NZ (1) NZ319891A (hu)
PL (1) PL325953A1 (hu)
SK (1) SK40198A3 (hu)
TR (1) TR199800573T2 (hu)
WO (1) WO1997011605A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110898A (en) * 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
EP1056842A2 (en) * 1998-02-11 2000-12-06 Maxygen, Inc. Genetic vaccine vector engineering
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2370646A1 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization
US6875612B2 (en) 2001-03-30 2005-04-05 Greenville Hospital System Monocyte-specific particulate delivery vehicle
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US11529414B2 (en) 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Also Published As

Publication number Publication date
PL325953A1 (en) 1998-08-17
HUP9802651A3 (en) 2001-08-28
NZ319891A (en) 1999-01-28
EP0863704A4 (en) 2003-09-10
CA2233278A1 (en) 1997-04-03
JPH11512724A (ja) 1999-11-02
AU716497B2 (en) 2000-02-24
NO981386D0 (no) 1998-03-26
BG102355A (en) 1999-04-30
CN1201369A (zh) 1998-12-09
SK40198A3 (en) 1998-11-04
WO1997011605A1 (en) 1997-04-03
CZ92998A3 (cs) 1998-09-16
TR199800573T2 (xx) 1998-07-21
AU7251596A (en) 1997-04-17
NO981386L (no) 1998-05-28
KR19990063672A (ko) 1999-07-26
EP0863704A1 (en) 1998-09-16

Similar Documents

Publication Publication Date Title
Staveley-O’Carroll et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression
Basham et al. Recombinant interferon-gamma increases HLA-DR synthesis and expression.
Mattei et al. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation
Irvine et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
Hui et al. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation
Pampena et al. Natural killer cells as helper cells in dendritic cell cancer vaccines
HUP0004611A2 (hu) APRIL, egy új növekedési hatású fehérje
GR3031026T3 (en) Lysosomal targeting of immunogens.
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
HUP9802651A2 (hu) Oltóanyagok részecskék célba juttatásával végzett genetikai immunizálással kiváltott, sejtközvetített immunválasz stimulálására
Streit et al. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms
US9757440B2 (en) Method for treating cancer with Toxoplasma gondii vaccine
Ohata et al. Enhanced efficacy of regulatory T cell transfer against increasing resistance, by elevated Foxp3 expression induced in arthritic murine hosts
Wang et al. Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice
Kuczma et al. Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells
DK0843731T3 (da) Adenovirusvektorer til genterapi
Staege et al. Functional and molecular characterization of interleukin‐2 transgenic Ewing tumor cells for in vivo immunotherapy
Delman et al. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer
Dezfouli et al. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cells
Xu et al. Genetic modulation of tumor antigen presentation
Ramesh et al. Enhancement of tumor killing using a combination of tumor immunization and HSV‐tk suicide gene therapy
Suzuki et al. IFN-γ production by brain-resident cells activates cerebral mRNA expression of a wide spectrum of molecules critical for both innate and T cell-mediated protective immunity to control reactivation of chronic infection with Toxoplasma gondii
Dunnion et al. Human antigen‐presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour‐associated antigens to cytotoxic T cells in vitro
Lode et al. DNA minigene vaccination for adjuvant neuroblastoma therapy